Case Reports
doi: 10.1515/jpem.2008.21.4.381.
Anaphylactic reaction to recombinant insulin-like growth factor-I
Affiliations
- PMID: 18556970
- DOI: 10.1515/jpem.2008.21.4.381
Item in Clipboard
Case Reports
Anaphylactic reaction to recombinant insulin-like growth factor-I
J Pediatr Endocrinol Metab.
2008 Apr.
Abstract
Mecasermin [rDNA] (Increlex; Tercica, Inc.) is recombinant insulin-like growth factor-I (IGF-I) that has been approved to treat growth failure in children with severe primary IGF-I deficiency. Serious allergic reactions related to Increlex therapy have not been reported. We report a 13 year-old male who developed life-threatening anaphylaxis early in the course of Increlex therapy.
Similar articles
-
A two year observation of the process of applying recombinant IGF-1 to treat short stature in children with primary IGF-1 deficiency -- case reports of 3 patients.Pediatr Endocrinol Diabetes Metab. 2011;17(4):233-8. Pediatr Endocrinol Diabetes Metab. 2011. PMID: 22248785
-
Mecasermin Tercica.Curr Opin Investig Drugs. 2006 Apr;7(4):371-80. Curr Opin Investig Drugs. 2006. PMID: 16625824 Review.
-
Insulin-like growth factor-I deficiency in children with growth hormone insensitivity: current and future treatment options.BioDrugs. 2009;23(3):155-63. doi: 10.2165/00063030-200923030-00002. BioDrugs. 2009. PMID: 19627167 Review.
-
Managing the child with severe primary insulin-like growth factor-1 deficiency (IGFD): IGFD diagnosis and management.Drugs R D. 2014 Mar;14(1):25-9. doi: 10.1007/s40268-014-0039-7. Drugs R D. 2014. PMID: 24639006 Free PMC article. Review.
-
Mecasermin rinfabate: insulin-like growth factor-I/insulin-like growth factor binding protein-3, mecaserimin rinfibate, rhIGF-I/rhIGFBP-3.Drugs R D. 2005;6(2):120-7. doi: 10.2165/00126839-200506020-00008. Drugs R D. 2005. PMID: 15777106 Review.
Cited by
-
Recombinant Human Insulin-Like Growth Factor-1 Treatment: Prime Time or Timeout? [Commentary on "Recombinant Human Insulin Like Growth Factor-1 Treatment: Ready for Prime Time" by Bright GM, Mendoza JR, Rosenfeld RG, Endocrinol Metab Clin N Am 2009; 38:625-38].Int J Pediatr Endocrinol. 2009;2009:429684. doi: 10.1155/2009/429684. Epub 2010 Feb 8. Int J Pediatr Endocrinol. 2009. PMID: 20169131 Free PMC article. No abstract available.
-
Primum non nocere (first, not to harm) and secundus, opinio vulnero (second, report the harm).Int J Pediatr Endocrinol. 2009;2009:303509. doi: 10.1155/2009/303509. Epub 2009 Mar 4. Int J Pediatr Endocrinol. 2009. PMID: 19946404 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
